Abstract
Glycogen phosphorylase (GP) has been firmly proved as an important target for treatment of type 2 diabetes. With the rapid increase of type 2 diabetic patients recently, it is becoming an interesting field to discover GP inhibitor for potential antidiabetic drugs. As GP is a typical allosteric protein with several key inhibitor binding sites including the inhibitor, the catalytic, the allosteric and the new allosteric sites, the research works were mainly focused on compounds that can bind these sites and show selective inhibitory effect. This paper mainly reviewed the advances in the design of inhibitors for different binding sites of GP and aimed at providing readers with some useful hints towards more effective GP inhibitors.
Keywords: Glycogen phosphorylase, inhibitors, binding sites, type 2 diabetes, allosteric protein, metabolism, gluconeogenesis, cyclodextrins, van der Waals bonds, riboflavin
Current Enzyme Inhibition
Title:Recent Advances in Design of Glycogen Phosphorylase Inhibitors
Volume: 7 Issue: 4
Author(s): Li Wen-Liang, Chen Jian, Luo Mei-Hong, Lu Han, Ma Li, Li Wei-Lin
Affiliation:
Keywords: Glycogen phosphorylase, inhibitors, binding sites, type 2 diabetes, allosteric protein, metabolism, gluconeogenesis, cyclodextrins, van der Waals bonds, riboflavin
Abstract:
Glycogen phosphorylase (GP) has been firmly proved as an important target for treatment of type 2 diabetes. With the rapid increase of type 2 diabetic patients recently, it is becoming an interesting field to discover GP inhibitor for potential antidiabetic drugs. As GP is a typical allosteric protein with several key inhibitor binding sites including the inhibitor, the catalytic, the allosteric and the new allosteric sites, the research works were mainly focused on compounds that can bind these sites and show selective inhibitory effect. This paper mainly reviewed the advances in the design of inhibitors for different binding sites of GP and aimed at providing readers with some useful hints towards more effective GP inhibitors.
Export Options
About this article
Cite this article as:
Li Wen-Liang, Chen Jian, Luo Mei-Hong, Lu Han, Ma Li, Li Wei-Lin , Recent Advances in Design of Glycogen Phosphorylase Inhibitors, Current Enzyme Inhibition 2011; 7 (4) . https://dx.doi.org/10.2174/157340811799860533
DOI https://dx.doi.org/10.2174/157340811799860533 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
HPLC Stability Indicating Assay Method for Metformin Hydrochloride in Bulk Drug and Tablets and Cytotoxicity of Degradation Products
Current Pharmaceutical Analysis WISP1 (CCN4) Autoregulates its Expression and Nuclear Trafficking of β-Catenin during Oxidant Stress with Limited Effects upon Neuronal Autophagy
Current Neurovascular Research Changes in Immune and Endocrine Systems in Scrapie-Infected Animals
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Far-infrared Ray-mediated Antioxidant Potentials are Important for Attenuating Psychotoxic Disorders
Current Neuropharmacology Duration of Dual Antiplatelet Therapy After Coronary Stenting
Current Pharmaceutical Design Ghrelin and Metabolic Disorders
Current Protein & Peptide Science Non-dipping Status in Arterial Hypertension: An Overview
Current Vascular Pharmacology Endothelial Dysfunction in Dyslipidaemia: Molecular Mechanisms and Clinical Implications
Current Medicinal Chemistry T-Lymphocytes: A Target for Stimulatory and Inhibitory Effects of Zinc Ions
Endocrine, Metabolic & Immune Disorders - Drug Targets Anti-diabetic Activity of Rosmarinic Acid Rich Fractions from Orthosiphon stamineus
Current Enzyme Inhibition Science of the Science, Drug Discovery and Artificial Neural Networks
Current Drug Discovery Technologies Recent Patents on Oral Insulin Delivery
Recent Patents on Drug Delivery & Formulation Editorial: The New Trial EMPAREG-OUTCOMES in Type 2 Diabetes: “and Death Shall Have no Dominion”?
Current Vascular Pharmacology Pericyte Loss in Diabetic Retinopathy: Mechanisms and Consequences
Current Medicinal Chemistry Age Matching Animal Models to Humans - Theoretical Considerations
Current Drug Discovery Technologies Greener Liquid Chromatography for Simultaneous Determination of Rosiglitazone and Glimepiride in Rat Sera and its Application to a Pharmacokinetic Study
Current Analytical Chemistry Epidemiology and Etiology of Alzheimer’s disease: From Genetic to Non- Genetic Factors
Current Alzheimer Research Diabetes and Vascular Disease: Basic Concepts of Nitric Oxide Physiology, Endothelial Dysfunction, Oxidative Stress and Therapeutic Possibilities
Current Vascular Pharmacology Pleiotropic Effects of HDL: Towards New Therapeutic Areas for HDL-Targeted Interventions
Current Molecular Medicine Swimming Impacts on Pancreatic Inflammatory Cytokines, miR-146a and NF-кB Expression Levels in Type-2 Diabetic Rats
Current Diabetes Reviews